Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis without significant alcohol consumption or concomitant liver disease. Patients with NAFLD-related cirrhosis are at a high risk of developing liver complications, including hepatocellular carcinoma (HCC).
Nonalcoholic fatty liver disease (NAFLD) refers to the development of hepatic steatosis in the absence of secondary causes. Contrarily to nonalcoholic steatohepatitis (NASH), which refers to inflammation and ballooning with or without fibrosis, NAFLD involves all histopathological changes.
The systemic immune-inflammation index (SII) is an integrated biomarker which may indicate systemic inflammation and local immune responses in the whole human body.
MAFLD and inflammatory bowel disease: a prospective cohort study
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
The authors considered NAFLD evaluation, diagnosis, and management in the primary care setting and endocrinology clinics.
The authors investigated the superiority of MAFLD versus NAFLD in predicting the risk of atherosclerotic cardiovascular disease.